Intravenous carbamazepine: a new formulation of a familiar drug

ABSTRACT

Introduction: Oral carbamazepine (CBZ), a broad-spectrum antiseizure drug (ASD) widely used for over 50 years, remains an important treatment choice for focal (partial) epilepsy. Although CBZ is a known inducer of cytochrome P450 (CYP) isoenzymes, many prescribers fail to recognize the potential issues with CBZ induction and are therefore unaware of the risk of drug toxicity upon CBZ withdrawal.

Areas covered: Managing concomitant medications in CBZ-treated patients can be difficult. Abruptly stopping CBZ treatment, as may occur when patients are unable to take oral medication, can affect plasma concentrations of other medications. An intravenous (IV) formulation of CBZ has been recently approved by the US FDA for short-term replacement therapy in patients with focal and generalized seizures. Use of IV CBZ allows maintenance of stable plasma concentrations in circumstances when oral administration is temporarily impractical.

Expert commentary: CBZ remains a frequently used treatment for focal seizures. With knowledge of the potential issues related to de-induction upon CBZ withdrawal, continuity of care with IV CBZ is an important step in improving the overall care of CBZ-treated patients.

KEYWORDS:

• Antiseizure drug
• carbamazepine
• focal seizures
• generalized seizures
• intravenous

Information resources

• http://www.epilepsy.com

• https://www.cdc.gov/epilepsy/index.html

• https://medlineplus.gov/epilepsy.html

• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58:181–221.

• Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 2006;62:291–6.

• Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16:409–31.

Acknowledgments

Medical writing and editorial assistance was provided by Jennifer Kaiser, PhD and Kristen A. Andersen, PhD of Prescott Medical Communications Group (Chicago, IL), funded by Lundbeck LLC, Deerfield, IL.

Declaration of interest

P Klein is a speaker for Eisai, Sunovion, and UCB Pharma, is on the advisory board for Lundbeck, Sunovion, and UCB Pharma, and has received research grants from Eisai and Lundbeck. D Tolbert is an employee at Lundbeck. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was funded by Lundbeck LLC.